Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis.

ABSTRACT: Currently, 15 randomized controlled trials (RCTs) have been designed to investigate whether neoadjuvant therapy (NAT) benefits patients with resectable pancreatic adenocarcinoma (R-PA) compared to surgery alone. Five of them have acquired results so far; however, corresponding conclusions have not been obtained. We speculated that the reason for this phenomenon could be that some prognostic factors had proven to be adverse through upfront surgery curative patterns, but some of them were not regarded as independent baseline characteristics, which is important to obtaining comparability between the NAT and upfront surgery groups. This fact could cause bias and lead to the difference in the outcomes of RCTs. In this review, we collate data about risk factors (such as tumor size, resection mar

SUBMITTER: Zhang HQ 

PROVIDER: S-EPMC9611436 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature